Cargando…

Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy

Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (irAEs) continues to rise, and rare toxicity continu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falade, Ayo S., Reynolds, Kerry L., Zubiri, Leyre, Deshpande, Vikram, Fintelmann, Florian J., Dougan, Michael, Mooradian, Meghan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049212/ https://www.ncbi.nlm.nih.gov/pubmed/35493494 http://dx.doi.org/10.3389/fimmu.2022.871452

Ejemplares similares

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
por: Hughes, Michael S., et al.
Publicado: (2019)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
por: Dougan, Michael
Publicado: (2017)

Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report
por: Leblanc, Julie, et al.
Publicado: (2021)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin
por: Qiu, Junlin, et al.
Publicado: (2022)

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
por: Fang, Wei, et al.
Publicado: (2023)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
por: Barham, Whitney, et al.
Publicado: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Zubiri, Leyre, et al.
Publicado: (2021)

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
por: Hughes, Michael S., et al.
Publicado: (2019)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021)

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
por: Reynolds, Kerry, et al.
Publicado: (2018)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
por: Drobni, Zsofia D., et al.
Publicado: (2022)

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
por: Appleton, Elizabeth, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
por: Zhao, Yujie, et al.
Publicado: (2022)

The metastatic dissemination of a squamous cell carcinoma arising from an epidermal cyst and subsequent failure to respond to programmed death 1 inhibition
por: Lumish, Melissa A., et al.
Publicado: (2019)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kalinich, Mark, et al.
Publicado: (2021)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
por: Mougel, Alice, et al.
Publicado: (2019)

Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
por: Eckert, Franziska, et al.
Publicado: (2019)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
por: Drobni, Zsofia D., et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Immune Checkpoints as Therapeutic Targets in Autoimmunity
por: Paluch, Christopher, et al.
Publicado: (2018)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
por: Grasselly, Chloé, et al.
Publicado: (2018)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
por: Ge, Zhouhong, et al.
Publicado: (2021)

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
por: Yang, Ximing, et al.
Publicado: (2022)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
por: Principe, Nicola, et al.
Publicado: (2022)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qmks35af03iqni1g2f38m71s1n